224 related articles for article (PubMed ID: 17901804)
1. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand.
Puthanakit T; Aurpibul L; Oberdorfer P; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V
Pediatr Infect Dis J; 2007 Oct; 26(10):953-6. PubMed ID: 17901804
[TBL] [Abstract][Full Text] [Related]
2. Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy.
Fraaij PL; Verweel G; van Rossum AM; van Lochem EG; Schutten M; Weemaes CM; Hartwig NG; Burger DM; de Groot R
Clin Infect Dis; 2005 Feb; 40(4):604-8. PubMed ID: 15712085
[TBL] [Abstract][Full Text] [Related]
3. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.
Flynn PM; Rudy BJ; Douglas SD; Lathey J; Spector SA; Martinez J; Silio M; Belzer M; Friedman L; D'Angelo L; McNamara J; Hodge J; Hughes MD; Lindsey JC;
J Infect Dis; 2004 Jul; 190(2):271-9. PubMed ID: 15216461
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
Song R; Jelagat J; Dzombo D; Mwalimu M; Mandaliya K; Shikely K; Essajee S
Pediatrics; 2007 Oct; 120(4):e856-61. PubMed ID: 17846147
[TBL] [Abstract][Full Text] [Related]
5. Low immunologic response to highly active antiretroviral therapy in naive vertically human immunodeficiency virus type 1-infected children with severe immunodeficiency.
Resino S; Alvaro-Meca A; de José MI; Martin-Fontelos P; Gutiérrez MD; Léon JA; Ramos JT; Ciria L; Muñoz-Fernández MA
Pediatr Infect Dis J; 2006 Apr; 25(4):365-8. PubMed ID: 16567992
[TBL] [Abstract][Full Text] [Related]
6. Initiation of highly active antiretroviral therapy in advanced AIDS with CD4 < 50 cells/mm3 in a resource-limited setting: efficacy and tolerability.
Sungkanuparph S; Kiertiburanakul S; Manosuthi W; Kiatatchasai W; Vibhagool A
Int J STD AIDS; 2005 Mar; 16(3):243-6. PubMed ID: 15829026
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.
Kline MW; Rugina S; Ilie M; Matusa RF; Schweitzer AM; Calles NR; Schwarzwald HL
Pediatrics; 2007 May; 119(5):e1116-20. PubMed ID: 17420261
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.
Puthanakit T; Aurpibul L; Sirisanthana T; Sirisanthana V
Pediatr Infect Dis J; 2009 Mar; 28(3):246-8. PubMed ID: 19165130
[TBL] [Abstract][Full Text] [Related]
9. Impact on weight and height with the use of HAART in HIV-infected children.
Guillén S; Ramos JT; Resino R; Bellón JM; Muñoz MA
Pediatr Infect Dis J; 2007 Apr; 26(4):334-8. PubMed ID: 17414398
[TBL] [Abstract][Full Text] [Related]
10. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model.
Chu H; Gange SJ; Yamashita TE; Hoover DR; Chmiel JS; Margolick JB; Jacobson LP
Am J Epidemiol; 2005 Oct; 162(8):787-97. PubMed ID: 16135508
[TBL] [Abstract][Full Text] [Related]
11. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
[TBL] [Abstract][Full Text] [Related]
13. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response.
Kovacs A; Montepiedra G; Carey V; Pahwa S; Weinberg A; Frenkel L; Capparelli E; Mofenson L; Smith E; McIntosh K; Burchett SK;
J Infect Dis; 2005 Jul; 192(2):296-302. PubMed ID: 15962224
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy.
Tangsinmankong N; Kamchaisatian W; Day NK; Sleasman JW; Emmanuel PJ
Ann Allergy Asthma Immunol; 2004 May; 92(5):558-64. PubMed ID: 15191025
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
[TBL] [Abstract][Full Text] [Related]
16. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
17. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy.
Weinberg A; Gona P; Nachman SA; Defechereux P; Yogev R; Hughes W; Wara D; Spector SA; Read J; Elgie C; Cooper M; Dankner W;
J Infect Dis; 2006 Jan; 193(2):302-11. PubMed ID: 16362896
[TBL] [Abstract][Full Text] [Related]
18. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy.
Brumme ZL; Brumme CJ; Chui C; Mo T; Wynhoven B; Woods CK; Henrick BM; Hogg RS; Montaner JS; Harrigan PR
J Infect Dis; 2007 Jun; 195(11):1694-704. PubMed ID: 17471440
[TBL] [Abstract][Full Text] [Related]
19. Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy.
Weinberg A; Wiznia AA; LaFleur BJ; Shah S; Levin MJ
J Infect Dis; 2004 Jul; 190(2):267-70. PubMed ID: 15216460
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients.
Palladino C; Briz V; Policarpo SN; Silveira LF; de José MI; González-Tomé MI; Moreno D; León Leal JA; Mellado MJ; de Ory SJ; Ramos JT; Muñoz-Fernández MA
Pediatr Infect Dis J; 2010 Jun; 29(6):563-6. PubMed ID: 20160659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
